Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed and Reolysin (and safety run-in)
Drug: Pemetrexed
Drug: Docetaxel and Reolysin
Drug: Docetaxel

First Posted Date: 2012-10-17

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 166

Registration Number: NCT01708993

Locations: 🇨🇦
Lakeridge Health Oshawa, Oshawa, Ontario, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 9 locations

Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab
Drug: Bevacizumab

First Posted Date: 2012-08-10

Last Posted Date: 2019-05-31

Lead Sponsor: Queen's University

Target Recruit Count: 10

Registration Number: NCT01661946

Locations: 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

Bronchodilating and Bronchoprotective Effects of Deep Inspirations

Not Applicable

Completed

Conditions: Asthma
Cough

Interventions: Other: Methacholine(MCh) Challenge Testing

First Posted Date: 2012-08-07

Last Posted Date: 2018-04-06

Lead Sponsor: Queen's University

Target Recruit Count: 43

Registration Number: NCT01659476

Locations: 🇨🇦
Kingston General Hospital at Queen's University, Kingston, Ontario, Canada

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Procedure: Radical Hysterectomy + pelvic lymph node dissection
Procedure: Simple hysterectomy + pelvic lymph node dissection

First Posted Date: 2012-08-07

Last Posted Date: 2024-12-17

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 700

Registration Number: NCT01658930

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇩🇪
Agaplesion Diakonieklinikum Hamburg, Hamburg, Germany

and more 82 locations

A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Reolysin

First Posted Date: 2012-08-03

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 81

Registration Number: NCT01656538

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 4 locations

Improving Bowel Preparation for the Colon Capsule

Phase 3

Completed

Conditions: Quality of Bowel Preparation for the Colon Capsule
Colon Capsule Completion Rates
Colon Capsule Polyp Detection

Interventions: Drug: PEG
Drug: Prucalopride
Drug: Picosalax
Procedure: Colon capsule
Drug: Bisacodyl
Procedure: Colonoscopy

First Posted Date: 2012-08-01

Last Posted Date: 2015-12-03

Lead Sponsor: Queen's University

Target Recruit Count: 20

Registration Number: NCT01655095

Locations: 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

Volunteers Adding Life in Dementia

Not Applicable

Completed

Conditions: Alzheimer Disease
Dementia
Behavior

Interventions: Behavioral: Volunteers Adding Life in Dementia (VALID) Program

First Posted Date: 2012-07-20

Last Posted Date: 2017-04-14

Lead Sponsor: Queen's University

Target Recruit Count: 75

Registration Number: NCT01646723

Locations: 🇨🇦
Extendicare Kingston, Kingston, Ontario, Canada

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Folfox plus Bevacizumab
Drug: Folfox plus Bevacizumab and reolysin

First Posted Date: 2012-06-19

Last Posted Date: 2023-08-23

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 109

Registration Number: NCT01622543

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada

and more 7 locations

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel, Reolysin and Prednisone
Drug: Docetaxel and Prednisone

First Posted Date: 2012-06-14

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 85

Registration Number: NCT01619813

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 8 locations

The Effect of Pre-operative Pelvic Floor Muscle Exercise on Surgical Outcomes in Women With Stress Urinary Incontinence

Not Applicable

Completed

Conditions: Stress Urinary Incontinence

Interventions: Other: Pelvic Floor muscle strengthening exercises

First Posted Date: 2012-05-18

Last Posted Date: 2017-11-07

Lead Sponsor: Queen's University

Target Recruit Count: 176

Registration Number: NCT01602107

Locations: 🇨🇦
School of Rehabilitation Therapy, Queen's University, Kingston, Ontario, Canada
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
Montfort Hospital, Ottawa, Ontario, Canada

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy